Press Release
Shire plc announces results for the first quarter 2007.
April 25, 2007
Q1 2007 Financial Highlights
- Product sales up 33% to 2 million;
- Total revenues up 29% to 8 million; and
- US GAAP Diluted EPS up 78% and Non GAAP Diluted EPS up 39%.
To view the full announcement please visit our website http://www.shire.com and go to the Latest News.
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
More from Dods
Advertise
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
